Drug Topics

NOVEMBER 8, 2022

Follow-ups from pharmacists show a significant increase in outpatient antiemetic drugs prescribed and quality of life in patients experiencing chemotherapy-induced nausea and vomiting.

Chemotherapy 144

Chemotherapy 144

Fierce Pharma

JUNE 5, 2023

Johnson & Johnson’s Balversa can keep some metastatic bladder cancer patients alive longer than chemotherapy, according to a study of 266 who have fibroblast growth factor receptor (FGFR) gene | Johnson & Johnson’s Balversa can keep some metastatic bladder cancer patients alive longer than chemotherapy, according to a study of 266 who have (..)

Chemotherapy 92

Chemotherapy 92

Pharmacy Times

SEPTEMBER 2, 2022

DNA and RNA sequencing could provide insight about resistance to chemotherapy in patients suffering from triple-negative breast cancer.

Chemotherapy 156

Chemotherapy 156

Fierce Pharma

JULY 21, 2023

This week on "The Top Line," we discuss the chemotherapy drug shortage, plus Grail’s harassment lawsuit and the rest of this week’s headlines In this episode of "The Top Line," we talk with Vimala Raghavendran, the vice president of informatics and product development at U.S.

Chemotherapy 92

Chemotherapy 92

European Pharmaceutical Review

APRIL 7, 2023

A new, sustained-release chemotherapy delivery device inserted into the bladder, facilitated tumour response, a study has reported. The intravesical device, TAR-200, provides continuous, low-dose, local delivery of gemcitabine chemotherapy. All patients had transurethral resection of bladder tumour (TURBT) to remove visible tumour.

Chemotherapy 79

Chemotherapy Mayo Clinic 79

Pharmacy Times

AUGUST 4, 2023

The affect of an aerobic exercise program was more prevalent in patients with ovarian cancer who had at least 1 symptom of chemotherapy-induced peripheral neuropathy at the beginning of the trial.

Chemotherapy 65

Chemotherapy 65

Pharmafile

MARCH 3, 2023

Scientists from the Institute of Cancer Research London, Imperial College London and the Netherlands Cancer Institute have researched a gene test which can select which advanced bowel cancer patients will respond the best to chemotherapy. read more

Chemotherapy 83

Chemotherapy Communication 83

The Guardian - Pharmaceutical Industry

JULY 7, 2023

Three health regulators have launched inquiries into the incident, according to people familiar with the matter.

Chemotherapy 93

Chemotherapy 93

Drug Topics

SEPTEMBER 6, 2022

Patients who received the chemotherapies paclitaxel and docetaxel were at an increased risk of adverse events of the eye.

Chemotherapy 98

Chemotherapy 98

Hospital Pharmacy Europe

FEBRUARY 14, 2023

The use of neoadjuvant chemotherapy has been shown to be of value at reducing tumour size and stage in patients with other operable cancers such as gastric and lower oesophageal adenocarcinomas. Neoadjuvant chemotherapy and cancer surgery outcomes A total of 686 patients assigned to NAC and 351 control patients were included in the analysis.

Chemotherapy 52

Chemotherapy Hospitals 52

Pharmacy Times

JULY 17, 2023

Chemotherapy may increase inflammatory biomarkers that can impact the diversity of the gut microbiome, leading to serious anthropomorphic changes among women treated for early-stage breast cancer.

Chemotherapy 65

Chemotherapy 65

STAT

JUNE 6, 2023

After finding a “cascade of failures” at a manufacturing plant run by a key chemotherapy supplier, the Food and Drug Administration will not allow the company to resume distribution in the U.S. beyond some   cancer medicines that are in short supply.

Chemotherapy 94

Chemotherapy FDA Documentation 94

Pharmafile

NOVEMBER 28, 2022

South Korean biotech firm Hyundai Bioscience’s innovative chemotherapy drug may be able to complete cancer treatments in two doses. The new anticancer drug, Polytaxel, is set to enter a clinical trial on pancreatic cancer being held in Australia. read more.

Chemotherapy 78

Chemotherapy 78

Pharmafile

APRIL 25, 2023

GSK has announced that the European Medicines Agency (EMA) has validated the company’s Type II Variation for a new indication for Jemperli (dostarlimab) alongside chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer.

Chemotherapy 59

Chemotherapy Communication 59

Pharmacy Times

JUNE 21, 2022

Two medical professionals reveal what factors into intensive chemotherapy consideration and common toxicities found when undergoing treatment.

Chemotherapy 65

Chemotherapy 65

Pharmaceutical Technology

JULY 7, 2023

Shorla Oncology has signed a licensing agreement with an undisclosed drug UK firm for a chemotherapy drug, PIP-101.

Chemotherapy 52

Chemotherapy 52

Pharmaceutical Technology

MARCH 30, 2023

The European Commission (EC) has granted approval for Regeneron Pharmaceuticals’ Libtayo (cemiplimab), along with platinum-based chemotherapy, as the first-line treatment for PD-L1 expression positive advanced non-small cell lung cancer (NSCLC) in adult patients.

Chemotherapy 52

Chemotherapy Immunization FDA 52

pharmaphorum

FEBRUARY 10, 2021

The PHERGain II study’s goal is to find an effective therapeutic strategy that can reduce the use of chemotherapy and improve the quality of life of patients without compromising the clinical effectiveness of their treatment.

Chemotherapy 98

Chemotherapy Hospitals 98

Pharmaceutical Technology

NOVEMBER 9, 2022

The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals ’ PD-1 inhibitor Libtayo (cemiplimab-rwlc) and chemotherapy combination as the first-line treatment for advanced non-small cell lung cancer (NSCLC). The regulatory approval is based on results obtained from the international Phase III EMPOWER-Lung 3 trial.

Chemotherapy 52

Chemotherapy FDA Adverse Reactions 52

Pharmacy Times

OCTOBER 6, 2022

Results from the largest head-to-head trial of programmed death receptor-1 inhibitors suggest that dostarlimab and chemotherapy could be an effective treatment option for patients with metastatic non-squamous non-small cell lung cancer.

Chemotherapy 65

Chemotherapy 65

Pharmacy Times

NOVEMBER 11, 2022

Tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy approved for the treatment of adults with metastatic non–small cell lung cancer without sensitizing EGFR mutation or ALK aberrations.

Chemotherapy 65

Chemotherapy FDA 65

Hospital Pharmacy Europe

AUGUST 30, 2022

Currently, it is recommended that stage I disease is treated with radiotherapy alone whereas concurrent chemotherapy (i.e., Despite the recommendation to combine IMRT and chemotherapy for patients with stage II NPC, there is a lack of supportive evidence for this approach. chemoradiotherapy) is advised for patients at stage II.

Chemotherapy 52

Chemotherapy Hospitals 52

Drug Topics

MAY 8, 2023

Patients with advanced or recurrent endometrial cancer treated with Keytruda plus chemotherapy had improved progression-free survival compared with chemotherapy alone.

Chemotherapy 187

Chemotherapy 187

Pharma Mirror

MARCH 8, 2021

The post The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy appeared first on Pharma Mirror Magazine. 2] Presumably, fenbendazole multitherapy along with this little. 2] Presumably, fenbendazole multitherapy along with this little.

Chemotherapy 98

Chemotherapy 98

Pharmacy Times

NOVEMBER 9, 2022

Efficacy results comparing the cemiplimab-rwlc combination to chemotherapy alone showed a 22-month median overall survival versus 13 months.

Chemotherapy 65

Chemotherapy FDA 65

Pharmacy Times

JUNE 27, 2023

Drug shortages are a common issue in the health care industry. Florida Cancer Specialists & Research Institute (FCS) is highly skilled at proactively managing the drug supplies it needs to care for patients.

Patient Care 94

Patient Care Chemotherapy 94

Pharmacy Times

APRIL 24, 2023

Efficacy and safety data for BeiGene’s therapy shows positive results for individuals with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Chemotherapy 123

Chemotherapy 123

Pharmacy Times

SEPTEMBER 6, 2022

Results from the TOPAZ-1 phase 3 trial showed that the combination reduced risk of death by 20% versus chemotherapy alone.

Chemotherapy 65

Chemotherapy 65

Pharmafile

FEBRUARY 1, 2023

It appears that adding veliparib to chemotherapy can extend progression-free survival (PFS) in patients suffering from triple negative breast cancer (TNBC) with a ‘BRCA-like’ phenotype. This conclusion follows results from the SWOG S1416 clinical trial, which was led by researchers at the SWOG Cancer Research Network. read more

Chemotherapy 52

Chemotherapy 52

Pharmacy Times

NOVEMBER 28, 2022

The trial data demonstrated that pembrolizumab in combination with chemotherapy also had statistically significant and clinically meaningful improvements in PFS and ORR as well.

Chemotherapy 65

Chemotherapy 65

pharmaphorum

NOVEMBER 9, 2021

Lung cancer drug Opdivo administered with chemotherapy has been shown to boost survival rates in patients with resectable non-small cell lung cancer (NSCLC). The post Opdivo and chemotherapy combo increases survival in lung cancer patients appeared first on.

Chemotherapy 59

Chemotherapy Immunization FDA 59

Drug Topics

JULY 25, 2023

Radiation therapy was associated with the largest increase, compared to chemotherapy or endocrine therapies.

Chemotherapy 187

Chemotherapy 187

Med Ed 101

NOVEMBER 10, 2021

Chemotherapy-induced nausea and vomiting (CINV) is one of the most common side effects in patients getting treated for cancer. The post Chemotherapy-Induced Nausea and Vomiting Update appeared first on Med Ed 101. Prevention for CINV is important to improve quality of life and treatment outcomes.

Chemotherapy 40

Chemotherapy 40

Pharmacy Times

SEPTEMBER 6, 2023

In addition to overall survival, main efficacy outcomes, such as progression-free survival, objective response rate, and time to response, were compared to chemotherapy alone.

Chemotherapy 123

Chemotherapy 123

Fierce Pharma

SEPTEMBER 22, 2023

As Seagen prepares for its takeover by Pfizer, the company’s Astellas-partnered cancer drug Padcev has chalked up a key trial win—in combination with Merck's Keytruda—in previously untreated metast | In a critical win, the Padcev-Keyturda combo significantly reduced the risk of death in first-line bladder cancer patients who are eligible for platinum-based (..)

Chemotherapy 108

Chemotherapy 108

Med Ed 101

APRIL 28, 2021

Some of the potential toxicities of common chemotherapeutics are outlined below in our Chemotherapy Toxicity Table. The post Chemotherapy Toxicity Table With Boxed Warnings appeared first on Med Ed 101. It is important to monitor patients closely for the development of toxicities during therapy.

Chemotherapy 40

Chemotherapy 40

Pharmacy Times

SEPTEMBER 7, 2023

Patients who received amivantamab plus chemotherapy or amivantamab without chemotherapy presented better outcomes compared to chemotherapy alone.

Chemotherapy 65

Chemotherapy 65